Grocery business Publix said on Tuesday that its is suspending the administration of the Johnson & Johnson COVID-19 vaccine at all of its pharmacy locations following guidance from the U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA).
The CDC and FDA have issued a joint media statement with additional information about the Johnson & Johnson COVID-19 vaccine.
While a rare side effect, individuals who have received the Johnson & Johnson COVID-19 vaccine should contact their health care provider if they develop a severe headache, abdominal pain, leg pain or shortness of breath within three weeks, according to the CDC and FDA.
However, the customers can visit publix.com/covidvaccine to schedule an appointment for the Moderna COVID-19 vaccine, if currently available in their state.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients